Product Overview
Composition
Active substance:
memantine hydrochloride 20 mg;
Excipients:
lactose,
MCC
silica colloidal
talc,
magnesium stearate,
Shell:
methacrylic acid copolymer,
sodium lauryl sulfate,
talc.
pharmachologic effect
Pharmacodynamics
Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the transmission of nerve impulses. Improves cognitive processes, increases daily activity.
Pharmacokinetics
After oral administration, Akatinol Memantine is rapidly and completely absorbed. The maximum plasma concentration is reached within 2-6 hours. With normal renal function, no cumulation of the drug was noted. Excretion proceeds in two phases. The elimination half-life is in the first phase - 4-9 hours, in the second phase - 40-65 hours.
It is excreted in urine.
Indications
Alzheimer's type dementia, vascular dementia, mixed dementia of all degrees of severity.
Contraindications
- individual hypersensitivity to the drug Akatinol Memantine;
- severe renal impairment;
- pregnancy;
- breast-feeding;
- children under 18 years old (due to insufficient data).
Carefully:
- thyrotoxicosis;
- epilepsy;
- convulsions (including history);
- myocardial infarction;
- heart failure.
Side effects
Adverse reactions are classified by clinical manifestations (in accordance with the defeat of certain organ systems) and by the frequency of occurrence:
| On the part of the body as a whole - general adverse reactions | Often | Headache |
| Seldom | Fatigability | |
| Infections | Seldom | Fungal infections |
| Mental disorders | Often | Drowsiness |
| Seldom | Confusion | |
| Seldom | Hallucinations 1 | |
| Frequency not set | Psychotic reactions 2 | |
| Disorders of the cardiovascular system | Seldom | Hypertension |
| Seldom | Venous Thrombosis / Thromboembolism | |
| Gastrointestinal Disorders | Often | Constipation |
| Seldom | Nausea, vomiting | |
| Frequency not set | Pancreatitis 2 | |
| Disorders from the central and peripheral nervous system | Often | Dizziness |
| Seldom | Gait impairment | |
| Rarely | Cramps |
1 Hallucinations have been observed mainly in patients with Alzheimer's disease in severe dementia.
2 There are separate reports of the occurrence of these adverse reactions when using the drug in clinical practice (data obtained after the drug was commercially available).
Interaction
With simultaneous use with barbiturates, antipsychotics, anticholinergics, the effect of the latter may be enhanced. When used together, it can change (strengthen or reduce) the effect of dantrolene or baclofen, so the doses of drugs should be selected individually.
How to take, course of administration and dosage
Akatinol Memantine is taken orally during meals. The dosage regimen is set individually. It is recommended to start treatment with the appointment of minimally effective doses.
Adults with dementia during the 1st week of therapy - at a dose of 5 mg / day, 2nd week - at a dose of 10 mg / day, 3rd week - at a dose of 15-20 mg / day. If necessary, a further weekly increase in dose of 10 mg is possible until a daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with increasing doses every week.
Overdose
Symptoms: increased severity of side effects.
Treatment: gastric lavage, intake of activated carbon, symptomatic therapy.
Special instructions
The optimal dose is achieved gradually, with increasing doses every week.
Release form
Coated tablets
